Prime wins patent fight with Beam to continue work on AATD gene editing therapy
From the article
Prime Medicine has come out ahead in its patent dispute with fellow gene-editing biotech Beam Therapeutics, after a panel of adjudicators ruled that the company did not violate its agreement with Beam and can continue developing its lead asset for alpha-1 antitrypsin deficiency.
Continue reading on Fierce BiotechYou might also wanna read
Amgen's PCSK9 Patent Battle: Legal Loss but Commercial Victory
This article examines Amgen's legal battle over PCSK9 cholesterol drugs, specifically their patent dispute with Sanofi and Regeneron. Amgen
alexkesin.com·9mo ago
Precision gene editing technologies: From proof-of-concept to clinical therapies
This review article examines the evolution of gene therapy from gene addition to precise genome editing, focusing on breakthrough technologi
cell.com·8d ago
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Bars·2d ago
CRISPR’s next act: the companies editing the epigenome to treat disease
go.nature.com·7d ago
Navigating the Complex Landscape of Cell and Gene Therapy Manufacturing
bioprocessintl.com·22d ago
FDA Draft Guidance Allows Gene Therapy Companies to Leverage Existing Data for Faster Product Approvals
The FDA released a new draft guidance on June 2 titled "Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorpo
jdsupra.com·26d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.